EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Somatic mutations in Middle East and North Africa breast cancer patients: a systematic review

Lama Abujamous, Isha Ahmed, Yasmin Ahen, Hadeel Alotaibi, Ala-Eddin Al Moustafa, Shereena Mohd Arif, Hamda Al-Thawadi, Rozami Razali iD

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf205 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The Oncologist, 2025. Verfasst von Lama Abujamous und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, Doha, Qatar. Hauptthemen laut MEDLINE: Breast Neoplasms, Mutation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Qatar University Internal.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Breast cancer presents with distinct clinical and molecular characteristics in the Middle East and North Africa (MENA) region, where women are diagnosed at younger ages and with more aggressive disease compared to Western populations. Despite the global burden, genomic studies of breast cancer in MENA remain underrepresented. This systematic review provides the first comprehensive analysis of somatic mutations in breast cancer patients across the MENA region.

Methods

Following PRISMA guidelines, we analyzed 44 studies encompassing 13 MENA countries, representing data from over 2500 breast cancer patients. Studies were rigorously assessed using the Newcastle-Ottawa Scale, with mutation data extracted, standardized, and classified according to pathogenicity using established databases. We employed multiple sequencing methodologies, including next-generation sequencing and targeted gene panels, to identify country-specific and region-wide mutation patterns.

Results

We identified 559 mutations across 104 genes, with TP53 (23.79%) and PIK3CA (10.19%) emerging as the most frequently altered genes, followed by significant mutations in BRCA1/2, ATM, ESR1, and PTEN. Nearly 43% of variants were classified as pathogenic/likely pathogenic, while 23% remained variants of uncertain significance. Missense mutations predominated (60.29%), followed by frameshift variants (13.06%) and stop-gained mutations (10.91%). We discovered distinctive country-specific mutation profiles, including unique alterations in KLF6 (Turkey) and IL-1β (Iraq), reflecting potential environmental and hereditary influences unique to MENA populations. Notably, all 11 PIK3CA hotspot mutations that predict sensitivity to alpelisib therapy were identified.

Conclusions

This study reveals both shared and distinct somatic mutation patterns in MENA breast cancer patients compared to Western populations. The high prevalence of clinically actionable mutations, particularly in PIK3CA and DNA repair genes, presents immediate opportunities for implementing targeted therapies across the region. Our findings underscore the urgent need for establishing a MENA Breast Cancer Genomics Consortium to standardize sequencing protocols, develop locally validated gene panels, and create regional variant databases that capture the unique mutation spectrum of these populations. This comprehensive genomic landscape of breast cancer in the MENA region addresses a critical gap in global cancer genomics, ultimately improving outcomes for a historically underrepresented patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsMutationHumansMiddle EastAfrica, NorthernFemaleHigh-Throughput Nucleotide Sequencing

Stichwörter der Autor:innen

PIK3CATP53breast cancer geneticsmutation profilingpersonalized oncologysomatic mutations

Autor:innen und Institutionen

  • Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, Doha, Qatar.
  • Office of Vice President for Research and Graduate Studies, Qatar University, Doha, Qatar.
  • Department of Biomedical Sciences, College of Health Science, QU Health, Qatar University, Doha, Qatar.
  • Oncology Department, McGill University, Montreal, Quebec H4A 3J1, Canada.
  • The National University of Malaysia in Qatar, Doha, Qatar.

ORCID-Profile: Rozami Razali

Förderung

  • Qatar University Internal

Zitieren

APA

Abujamous, L., Ahmed, I., Ahen, Y., Alotaibi, H., Al Moustafa, A. E., Mohd Arif, S., Al-Thawadi, H., & Razali, R. (2025). Somatic mutations in Middle East and North Africa breast cancer patients: a systematic review. The Oncologist. https://doi.org/10.1093/oncolo/oyaf205

Vancouver

Abujamous L, Ahmed I, Ahen Y, Alotaibi H, Al Moustafa AE, Mohd Arif S, et al. Somatic mutations in Middle East and North Africa breast cancer patients: a systematic review. The Oncologist. 2025. doi:10.1093/oncolo/oyaf205

BibTeX
@article{Abujamous2025,
  author = {Abujamous, Lama and Ahmed, Isha and Ahen, Yasmin and Alotaibi, Hadeel and Al Moustafa, Ala-Eddin and Mohd Arif, Shereena and Al-Thawadi, Hamda and Razali, Rozami},
  title = {Somatic mutations in Middle East and North Africa breast cancer patients: a systematic review},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf205}
}
Kostenlos starten →